Devices

Neuralink's visual prosthesis, which would stimulate visual cortex directly so that people without working eyes or optic nerves might perceive images. FDA breakthrough device designation in September 2024. Human results are not confirmed in the sources used here.

Device — Intracortical

Neuralink Blindsight

Official site →

Neuralink · Blindsight · visual prosthesis · visual cortex · breakthrough device · company · preclinical

Neuralink Blindsight

One-line verdict: A cortical visual prosthesis that skips the eye entirely. The designation is confirmed. Whether anyone has yet seen anything through it is not confirmed by a primary source we could find.

Quick tags: Stimulation · Visual cortex · US · Breakthrough designation September 2024

Overview

What it is: Blindsight is Neuralink’s visual prosthesis. Per Neuralink and Elon Musk’s statement quoted by Reuters, it is meant to let even people who have lost both eyes and their optic nerve see. Medical Device Network describes it as processing and transmitting neural signals, and says it depends on the visual cortex remaining intact.

Regulatory: The FDA granted breakthrough device designation, announced 17 September 2024. IEEE Spectrum quotes an FDA spokesperson saying the designation does not mean the device is safe or effective, and that it still has to go through full clinical trials.

Expectations: IEEE Spectrum’s headline for its September 2024 analysis is that Blindsight is likely to disappoint, and that it will not deliver natural sight. Compare the earlier cortical visual prosthesis in this catalog, the Dobelle implant.

Human status, unconfirmed: A Reuters report of 18 May 2026 says Musk expected Neuralink’s first Blindsight implant later in 2026. A third-party site, All Things Elon, reported on 30 September 2026 that a trial participant had perceived points of light. We found no Neuralink or Reuters source for that, so this entry does not treat it as established. Status is listed as preclinical until a primary source confirms a human result.

Spec Card Grid

Identity

  • Company: Neuralink
  • FDA breakthrough designation: announced 17 September 2024

Architecture

  • Target: visual cortex, bypassing eyes and optic nerve
  • Electrode count, dimensions, camera hardware: not given in the sources used here

Evidence and limits

  • Needs a primary source: any human result
  • No 3D model: no published geometry in the sources used here

References